Meiji Seika Pharma Co., Ltd.: CORRECTING and REPLACING Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis : vimarsana.com

(0)
First paragraph, third sentence of release dated May 20, 2021, should read: Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: JUNG Jae-Hun, "Dong-A"). (instead of Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: Jong Hyun Han, "Dong-A").).
The updated release reads:
MEIJI SEIKA PHARMA:
PROMISING RESULTS OF PHASE I CLINICAL TRIAL OF DMB-3115, A PROPOSED USTEKINUMAB BIOSIMILAR, AND INITIATION OF PHASE III CLINICAL TRIAL IN PATIENTS WITH PLAQUE PSORIASIS
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi, "Meiji") today announced that the bioequivalence of DMB-3115, a proposed ustekinumab biosimilar, has been demonstrated in phase I clinical trial compared to the reference products marketed in Europe and the United States. Meiji also announced the initiation of phase III multi-regional clinical trial in patients with plaque psoriasis. Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: JUNG Jae-Hun, "Dong-A").

Related Keywords

Seoul , Soult Ukpyolsi , South Korea , Japan , Tokyo , United States , Daikichiro Kobayashi , Kostenloser Wertpapierhandel , Jong Hyun Han , Business Development Dept , Donga Socio Holdings Headquarters , Meiji Seika Pharma Co Ltd , Donga Socio Holdings , Representative Director , Product Acquisition , Business Development , Meiji , Eika , Harma , Orrecting , Eplacing , Romising , Esults , Hase , Linical , Rial , 115 , Roposed , Stekinumab , Iosimilar , Nitiation , Atients , Ith , Laque , Soriasis , சியோல் , தெற்கு கொரியா , ஜப்பான் , டோக்கியோ , ஒன்றுபட்டது மாநிலங்களில் , வணிக வளர்ச்சி டெபிட் , டோங்கா சமூக ஹோல்டிங்ஸ் , பிரதிநிதி இயக்குனர் , ப்ராடக்ட் கையகப்படுத்தல் , வணிக வளர்ச்சி , மேஜி , ரியால் , இத் ,